Q3 2020 Sales Performance

Zejula Developing the most compelling PARP inhibitor in ovarian cancer 4L treatment Study start Read-out QUADRA pivotal following 3-4 regimens of chemotherapy open label, single arm study n= 461 2017 Complete Approved gsk Recurrent platinum resistant Recurrent maintenance therapy or treatment 1L monotherapy and combination with novel TOPACIO POC recurrent OC and advanced /metastatic TNBC niraparib + pembrolizumab (MK-3475) n=-120 2016 Complete Published in JAMA MOONSTONE* pivotal platinum resistant ovarian cancer Open label, single arm nira + dostarlimab n=-150 2H 2019 2021 Enrolling NOVA pivotal platinum sensitive niraparib vs. placebo following chemo n= 553 2013 Complete Approved AVANOVA** POC platinum sensitive niraparib vs niraparib + bev. n=-100 (part 1 and part 2 combined) 2015 Complete Best of ASCO 2019 PRIMA pivotal maintenance following CR/PR with frontline chemo niraparib monotherapy RTOR 2016 Complete Approved n=-620 OVARIO POC maintenance following frontline chemo+bev single arm, open label study of niraparib + bevacizumab 2018 2020 SGO 2020 presentation n=-100 FIRST agents pivotal maintenance in newly diagnosed advanced OC Combo w/dostarlimab +/- bevacizumab n=-620 2018 2023 Enrolling * Study temporarily held recruitment activities to perform a pre-planned interim analysis **Investigator sponsored study 48 48

View entire presentation